|Table of Contents|

Dual effects of proton pump inhibitors on digestive system tumors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 04
Page:
744-748
Research Field:
Publishing date:

Info

Title:
Dual effects of proton pump inhibitors on digestive system tumors
Author(s):
CAO Ming; ZHANG Xueyan
Department of Gastroenterology,the Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150086，China．
Keywords:
PPI; tumor; dual effect
PACS:
R735
DOI:
10.3969/j.issn.1672-4992.2022.04.041
Abstract:
Proton pump inhibitor (PPI) is the most effective medicine for treating peptic ulcer at present.By inhibiting H+/K+-atpase,PPI can effectively and rapidly inhibit gastric acid secretion,interfere with the survival of helicobacter pylori,and promote the healing of gastroduodenal ulcer.Since its discovery,it has been widely used in a variety of gastroduodenal diseases.In recent years,with the further study of proton pump inhibitors,it has been found that PPI can play an anticancer role by affecting certain signaling pathways,protein expression of tumor cells and blood concentration of certain chemotherapy drugs.However,some researchers have raised concerns about the serious side effects of long-term use of PPI.This article introduces the dual role of PPI in the development of digestive system tumors.

References:

[1]HUANG S,CHEN M,SHEN Y,et al.Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells ［J］.Cancer Lett,2012,315(2):198-205.
[2]HUANG S,CHEN M,DING X,et al.Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway ［J］.Int Immunopharmacol,2013,17(3):585-592.
[3]JUDD LM,BREDIN K,KALANTZIS A,et al. STAT3 activation regulates growth,inflammation,and vascularization in a mouse model of gastric tumorigenesisl ［J］.Gastroenterology,2006,131(4):1073-1085.
[4]TAI WT,CHENG AL,SHIAU CW,et al.Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3 ［J］.Mol Cancer Ther,2012,11(2):452-463.
[5]SUN T,DU W,XIONG H,et al.TMEFF2 deregulation contributes to gastric carcinogenesis and indicates poor survival outcome ［J］.Clin Cancer Res,2014,20(17):4689-4704.
[6]ZHANG B,LING T,ZHAXI P,et al.Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression ［J］.Cancer Lett,2019,452:23-30.
[7]YEO M,KIM DK,PARK HJ,et al.Blockage of intracellular proton extrusion with proton extrusions with proton pump inhibitor induces apoptosis in gastric cancer ［J］.Cancer Sci,2008,99(1):185.
[8]GU M,ZHANG Y,ZHOU X,et al.Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines ［J］.Oncol Lett,2014,8(4):1739-1744.
[9]TAKEDA A,TAKANO N,KOKUBA H,et al.Macrolide antibiotics enhance the antitumor effect of lansoprazole resulting in lysosomal membrane permeabilization-associated cell death［J］.Int J Oncol,2020,57(6):1280-1292.
[10]FENG S,QIU G,YANG L,et al.Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation［J］.Biosci Rep,2021,41(1):BSR20200842.
[11]PARKS SK,CHICHE J,POUYSSGUR J.Disrupting proton dynamics and energy metabolism for cancer therapy ［J］.Nat Rev Cancer,2013,13(9):611-623.
[12]KATARA GK,JAISWAL MK,KULSHRESTHA A,et al.Tumor-associated vacuolar ATPase subunit promotes tumorigenic characteristics in macrophages ［J］.Oncogene,2014,33(49):5649-5654.
[13]DE MILITO A,FAIS S.Proton pump inhibitors may reduce tumour resistance ［J］.Expert Opin Pharmacother,2005,6(7):1049-1054.
[14]SHEN Y,CHEN M,HUANG S,et al.Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2 ［J］.Oncol Lett,2016,11(1):717-722.
[15]TAN MC,GRAHAM DY.Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer ［J］.BMJ Evid Based Med,2018,23(3):111-112.
[16]DOCKRAY GJ,MOORE A,VARRO A,et al.Gastrin receptor pharmacology ［J］.Curr Gastroenterol Rep,2012,14(6):453-459.
[17]SMITH JP,SHIH AH,WOTRING MG,et al.Characterization of CCK-B/gastrin-like receptors in human gastric carcinoma ［J］.Int J Oncol,1998,12(2):411-419.
[18]FERRAND A,WANG TC.Gastrin and cancer:a review ［J］.Cancer Lett,2006,238(1):15-29.
[19]LUNDELL L,VIETH M,GIBSON F,et al.Systematic review:the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology ［J］.Aliment Pharmacol Ther,2015,42(6):649-663.
[20]HUANG L,QI DJ,HE W,et al.Omeprazole promotes carcinogenesis of fore-stomach in mice with co-stimulation of nitrosamine ［J］.Oncotarget,2017,8(41):70332-70344.
[21]KOBAYASHI J,UCHIDA H,ITO J.Long-term proton pump inhibitor use after Helicobacter pylori eradication may create a gastric environment for N-nitrosamine formation and gastric cancer development ［J］.Gut,2019,68(6):1131.
[22]JANKOWSKI JAZ,DE CAESTECKER J,LOVE SB,et al.Esomeprazole and aspirin in Barrett's oesophagus (AspECT):a randomised factorial trial ［J］.Lancet,2018,392(10145):400-408.
[23]PENG YC,LIN CL,HSU WY,et al.Proton pump inhibitor use is associated with risk of pancreatic cancer:A nested case-control study ［J］.Dose Response,2018,16(4):1559325818803283.
[24]HWANG IC,CHANG J,PARK SM.Association between proton pump inhibitor use and the risk of pancreatic cancer:A Korean nationwide cohort study ［J］.PLoS One,2018,13(9):e0203918.
[25]HONG HE,KIM AS,KIM MR,et al.Does the use of proton pump inhibitors increase the risk of pancreatic cancer? A systematic review and Meta-analysis of epidemiologic studies［J］.Cancers (Basel),2020,12(8):2220.
[26] MATBOLI M,ELGWAD AA,HASANIN AH,et al.Pantoprazole attenuates tumorigenesis via inhibition of exosomal secretion in a rat model of hepatic precancerous lesion induced by diethylnitrosamine and 2-acetamidofluorene［J］.J Cell Biochem,2019,120(9):14946-14959.
[27]ZENG X,LIU L,ZHENG M,et al.Pantoprazole,an FDA-approved proton-pump inhibitor,suppresses colorectal cancer growth by targeting T-cell-originated protein kinase ［J］.Oncotarget,2016,7(16):22460-22473.
[28]ZHENG M,LUAN S,GAO S,et al.Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase ［J］.Oncotarget,2017,8(24):39143-39153.
[29]CAO Y,CHEN M,TANG D,et al.The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses ［J］.Cell Death Dis,2018,9(6):604.
[30]ZHANG B,YANG Y,SHI X,et al.Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition ［J］.Cancer Lett,2015,356(2 Pt B):704-712.
[31]FENG S,ZHENG Z,FENG L,et al.Proton pump inhibitor pantoprazole inhibits the proliferation,self renewal and chemoresistance of gastric cancer stem cells via the EMT/β catenin pathways ［J］.Oncol Rep,2016,36(6):3207-3214.
[32]GUAN XW,ZHAO F,WANG JY,et al.Tumor microenvironment interruption:a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes ［J］.Am J Cancer Res,2017,7(9):1913-1925.
[33] ARAKI R,KEIRA T,MASUDA Y,et al.Effects of proton pump inhibitors on severe haematotoxicity induced after first course of pemetrexed/carboplatin combination chemotherapy ［J］.J Clin Pharm Ther,2019,44(2):276-284.
[34]JUNG D,HAN JM,YEE J,et al.Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients ［J］.Med Oncol,2018,35(12):154.
[35]KIM MK,YEE J,CHO YS,et al.Risk factors for erlotinib-induced hepatotoxicity:a retrospective follow-up study ［J］.BMC Cancer,2018,18(1):988.
[36]NARUMI K,SATO Y,KOBAYASHI M,et al.Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate:Evaluation of drug-drug interactions mediated by organic anion transporter 3 ［J］.Biopharm Drug Dispos,2017,38(9):501-508.
[37]BOERRIGTER E,CRUL M.A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin［J］.Ann Pharm Fr,2017,75(5):344-348.

Memo

Memo:
-
Last Update: 1900-01-01